{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:22:44Z","timestamp":1787757764585,"version":"build-2784847793"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      Migraine is characterized by severe, intermittent headache attacks with associated symptoms including nausea, vomiting, phonophobia, and photophobia. Still\n                      <jats:italic toggle=\"yes\">Triptans<\/jats:italic>\n                      (selective 5-HT\n                      <jats:sub>1B\/D<\/jats:sub>\n                      agonists) are considered as the first-line therapy in acute attack of migraine. Recently two new drugs\n                      <jats:italic toggle=\"yes\">Lasmiditan<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">Ubrogepant<\/jats:italic>\n                      were approved by United States Food and Drug Administration in acute attack of migraine with or without aura in adults. Lasmiditan is a highly selective 5-HT\n                      <jats:sub>1F<\/jats:sub>\n                      receptor agonist which demonstrated superiority to placebo in the acute treatment of migraine in adults with moderate\/severe migraine disability in two similarly designed phase-3 trials, SAMURAI and SPARTAN. Ubrogepant is a novel small molecule oral calcitonin gene-related peptide receptor antagonist. The approval was supported by two pivotal phase-3, randomized, double-blind, placebo-controlled trials (ACHIEVE I and ACHIEVE II) that evaluated the efficacy, safety, tolerability. Hopefully, these two drugs may soon be a new addition to the mounting armory of drugs against migraine and may fulfill a substantial unmet need.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0028-3886.333495","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T01:47:50Z","timestamp":1640656070000},"page":"1759-1762","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Newer Horizon for Treatment of Acute Attack of Migraine"],"prefix":"10.4103","volume":"69","author":[{"given":"Arpita","family":"Maitra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabyasachi","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouvik","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-50-20240907","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s10194-019-1017-9","article-title":"Advances in genetics of migraine","volume":"20","author":"Sutherland","year":"2019","journal-title":"J Headache Pain"},{"key":"R3-50-20240907","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s10194-019-1010-3","article-title":"Optimising migraine treatment: From drug-drug interactions to personalized medicine","volume":"20","author":"Pomes","year":"2019","journal-title":"J Headache Pain"},{"key":"R4-50-20240907","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.2147\/JPR.S152216","article-title":"Lasmiditan for the treatment of acute migraine: A review and potential role in clinical practice","volume":"11","author":"Oswald","year":"2018","journal-title":"J Pain Res"},{"key":"R6-50-20240907","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/14656566.2019.1694004","article-title":"Profiling lasmiditan as a treatment option for migraine","volume":"21","author":"Curto","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"R7-50-20240907","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40265-019-01225-7","article-title":"Lasmiditan: First approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"R8-50-20240907","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s10194-019-1032-x","article-title":"Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: Findings from SAMURAI and SPARTAN, two randomized phase 3 trials","volume":"20","author":"Loo","year":"2019","journal-title":"J Headache Pain"},{"key":"R9-50-20240907","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40265-020-01264-5","article-title":"Ubrogepant: First approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"R10-50-20240907","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11940-017-0463-4","article-title":"Anti-CGRP monoclonal antibodies: The next era of migraine prevention?","volume":"19","author":"Tso","year":"2017","journal-title":"Curr Treat Options Neurol"},{"key":"R11-50-20240907","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/head.13766","article-title":"Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials, ACHIEVE I and II","volume":"60","author":"Dodick","year":"2020","journal-title":"Headache"},{"key":"R12-50-20240907","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepantfor the treatment of migraine","volume":"381","author":"Dodick","year":"2019","journal-title":"N Engl J Med"},{"key":"R13-50-20240907","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of ubrogepantvs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: The ACHIEVE II randomized clinical trial","volume":"322","author":"Lipton","year":"2019","journal-title":"JAMA"},{"key":"R14-50-20240907","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40263-020-00715-7","article-title":"Safety and efficacy of ubrogepantfor the acute treatment of episodic migraine: A meta-analysis of randomized clinical trials","volume":"34","author":"Yang","year":"2020","journal-title":"CNS Drugs"}],"container-title":["Neurology India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.333495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:52:24Z","timestamp":1787755944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.333495"}},"subtitle":["Lasmiditan and Ubrogepant"],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/0028-3886.333495","relation":{},"ISSN":["0028-3886"],"issn-type":[{"value":"0028-3886","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}